<DOC>
	<DOCNO>NCT00792298</DOCNO>
	<brief_summary>A cross-over , polysomnography study test safety , tolerability effectiveness different dos suvorexant ( MK-4305 ) treatment patient primary insomnia .</brief_summary>
	<brief_title>Phase IIB 2-Period Crossover Polysomnography Study Participants With Primary Insomnia ( MK-4305-006 )</brief_title>
	<detailed_description />
	<mesh_term>Sleep Initiation Maintenance Disorders</mesh_term>
	<mesh_term>Suvorexant</mesh_term>
	<criteria>Has diagnosis Primary Insomnia base sleep history investigator 's judgment Must willing stay overnight sleep laboratory Must willing stay bed least 8 hour night sleep laboratory Regular bedtime 9 PM 12 AM ( midnight ) Breast feeding , pregnant planning become pregnant study Within past 6 month start study history significant cardiovascular disorder unstable angina , congestive heart failure acute coronary syndrome Currently participate participate study investigational compound device within last 30 day Has travel across 3 time zone last 2 week plan travel across 3 time zone time study Has do shift work within past 2 week Has donate blood product within last 8 week Has difficulty sleep due medical condition</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>64 Years</maximum_age>
	<verification_date>February 2015</verification_date>
</DOC>